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Abstract— One of the main causes of women’s cancer-related death is Epithelial Ovarian Cancer (EOC). A new spectrophotometric 
method was developed to determine a biomarker for EOC. This study aims to investigate the pattern of EDTA-blood photo spectrum 
in EOC patients. One ml blood was collected from sixty-six subjects (33 EOC patients, 33 healthy controls) by venipuncture, which 
then drawn into EDTA tubes for photo spectrum analysis. The t-test using programming in Matrix Laboratory (MATLAB) for 
Windows 7 tested the differences in ENBS and EBS parameters in the two groups and the parameters of EDTA-blood photo spectrum 
in two groups based on the energetics of non-biological systems (ENBS) and energetics of biological systems (EBS) approach. The 
statistical significance of p<0.01 was taken to evaluate the difference. The receivers operating characteristic (ROC) curves were 
applied to evaluate the effect of biomarkers on these parameters. The area under the ROC curve (AUC) is used to evaluate the 
biomarker with the correspondence interval (CI) of 95%. The t-test results indicate that the significant difference was observed 
between EOC patients and healthy controls only in parameter-1 of the parameters based on the ENBS approach. However, there 
were significant differences in all parameters based on the EBS approach. In a training dataset, the AUC values were 0.663, 0.704, 
0.546, 0.611, 0.619, and 0.676 for ideal parameter-1 to 6 (IP1-6); and 0.886, 0.855, 0.765, 0.909, 0.897, and 0.789 for real parameter-1 
to 6 (RP1-6). Sensitivity and specificity of IP1-6 = 48.5%, 42.4%, 24.2%, 57.6%,  84.8%, and 60.6%; and 100.0%, 100.0%, 97.0%, 
66.7%, 39.4%,  and 72.7% respectively, at cut-off point 1.0E-12, -1.3E-06, 3.2E-01, 7.2E-11, -2.7E-05, and 4.5E+00 respectively; 
whereas sensitivity and specificity of  RP1-6 = 100.0%, 100.0%, 84.8%, 100.0%, 100.0%, and 93.9%; and 93.9%, 90.9%, 81.8%, 
100.0%, 97.0%, and 81.8% respectively, at cut-off point 5.0E-04, 6.3E-04, -1.1E-03, 9.4E-03, -8.8E-03, and 9.8E-03 respectively. Thus, 
it could be concluded that parameters of the pattern of EDTA-blood photo spectrum based on the ENBS approach could be used to 
identify new biomarkers of EOC.  
  




The World Health Organization (WHO) reports that 
150,000 deaths from epithelial ovarian cancer (EOC) 
worldwide, there are around 22,000 new cases each year [1]. 
This cancer is "the most lethal gynecologic cancer.” The 
condition will be even worse if the patient is not diagnosed 
at an early stage [2]. In Indonesia, ovarian cancer is the third 
cause of death for women, in which 829 cases have been 
reported [3]. The gold standard for ovarian cancer is a 
biopsy that confirms the presence of neoplastic cell growth 
in the ovary. However, it can cause bleeding and infection 
due to needle insertion. The CA125 is a specific biomarker 
for ovarian cancer especially used to monitor therapy. The 
level increases in the early stadium of ovary cancer [4]. This 
increase is by the presence of malignancy in the ovary. The 
CA125 is a carbohydrate antigen with a negative charge due 
to the presence of terminal sialic acid residues [5]. Besides 
CA125, fibrinogen level in the blood increases in patients 
with malignancy. Fibrinogen plays an important role in the 
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coagulation process [6]. The CA125 and fibrinogen 
contribute to cellular interactions in the blood.  
Erythrocytes stick together and move toward the bottom 
of the container (sedimentation occurs) when anti-coagulated 
blood is allowed to stand quietly [7]. The process is 
commonly known as a rouleaux formation. Ethylene 
Diamine Tetra Acetic Acid (EDTA) is the common anti-
coagulant. This molecule affects the activity of the dissolved 
protein in plasma so that the occurrence of coagulation of 
erythrocytes can be prevented [8]. The erythrocyte 
sedimentation rate (ESR) depends on many factors, such as 
the level of plasma proteins that increase the rouleaux 
formation and the subsequent surface-to-volume ratio that 
favourserythrocyte sedimentation [9], [10].  
The Westergren method is a commonly used ESR 
measurement. This method is done by measuring the 
boundary between clear plasma and red corpuscles, which is 
the boundary between clear areas in the blood given 
anticoagulants (plasma regions) with cloudy areas 
(corpuscles) after being left on the Westergren pipette for 1 
hour. Despite its relatively low sensitivity and specificity in 
monitoring disease activity, the ESR assessment is a widely 
used, cost-effective and simple test, which may be a viable 
alternative to novel [11]. The spectrometry method can also 
be used to determine the ESR value by detecting changes in 
clarity in the upper part of blood-EDTA in a time series [12]. 
Statistically, data in time series can be divided into 
deterministic and stochastic components, which do not 
correlate with each other. Ordinary differential equations are 
used in deterministic approaches, based on the 
phenomenological law of mass action. However, in complex 
systems, systems whose changes occur randomly, 
deterministic approaches cannot be used, but the approach 
used is a stochastic model. Stochastic models, however, are 
more difficult to use for analysis than deterministic models 
[13]. This study aims to discover the parameters of the 
pattern of EDTA-blood photo spectrum in EOC patients by 
using a new approach based on the characteristics of the 
living system. The existing method is that the biomarker has 
to be isolated such that the biomarker with low concentration 
may not be observed, whereas in this new method, the 
biomarker need not be isolated. Hence, any small 
concentration of the biomarker suffices because it gives an 
effect to the erythrocyte interactions. 
II. MATERIALS AND METHODS  
A. Materials 
The study included 33 EOC patients diagnosed by the 
Gynecology Group and 33 healthy volunteers. The sample 
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where n is the sample size per group, α is 0.05, β is 0.2, σ2 is 
the population variance in meantime union (standard 
deviation), µ1 is the  population mean time to union in 
intramedullary  nail without reaming, µ2 is the population 
mean time to union intramedullary with reaming, and µ1 - µ2  
is the minimum important difference to detect in population 
mean time to union between group 1 and group 2. Based on 
equation (1), all sample size for the EBS parameter is 
satisfied, whereas for the ENB parameter only satisfies one 
parameter. 
The ovarian cancer patients have been hospitalized in 
RSUP Dr. Sardjito Hospital. The inclusion criteria of ovarian 
cancer patients are those whose age is in between 15 to 60 
years old with a positive result of ovarian cancer is based on 
histopathological examination. The study has been approved 
by the Medical and Health Ethical Review Committee of the 
Faculty of Medicine, UGM, number: KE/FK/888/EC/2015 
and all the patients gave their informed consent for the 
participation in the study. The patients have agreed to 
informed consent. Whereas, the exclusion criteria are 
patients who have a history of or are suffering from more 
than one type of cancer or any other diseases. Healthy 
subjects were those who have neither history of cancer nor 
recent sepsis and inflammation. Healthy subjects were not 
descendant from the cancer patient.  
B. Method 
This cross-sectional study was carried out in Dr. Sardjito 
Hospital and Biochemistry Laboratory, Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia in May 
2015 to December 2015. The cellular interaction pattern was 
observed by using the spectrophotometric method. Venous-
blood samples were obtained from ovarian cancer patients 
and healthy subjects. Three mL of venous blood was taken 
from each subject then filled into EDTA tubes: 1.0 mL for 
cellular interaction examination with the spectrophotometric 
method. The absorbance values were measured by 
spectrophotometry and observed every 4 seconds for 30 
minutes. Two mL was used for patient routine monitoring. 
From the graph of the pattern of absorbance versus the 
time, then obtained the parameters based on the energetics of 
non-biological system (ENBS) approach [15], [16], the 
researchers named the ENBS parameters. The value of the 
ENBS parameters is obtained from deterministic and 
stochastic analysis from the pattern of the absorbance versus 
the time. Furthermore, the new parameter is obtained from 
the ENBS parameter involving the cycle concept that is a 
characteristic of the living system [17], [18], the parameters 
based on the energetics of biological system (EBS) 
approach. This new parameter researchers name the EBS 
parameters. The t-test using programming in Matrix 
Laboratory (MATLAB) for Windows 7 tested the 
differences in ENBS and EBS parameters in the two groups. 
All Pvalueis statistically significant if it is below 0.01. The 
receiver operating characteristic (ROC) curves were applied 
to evaluate the effect of biomarkers on these parameters. The 
area under the ROC curve (AUC) is used to evaluate the 
presence of biomarkers reflected in EOC with a 
correspondence interval (CI) of 95%. The best cut-off value 
was determined based on the maximum sensitivity and 
specificity score as the optimal standard. Sensitivity and 
specificity value was calculated under the cut-off. The value 
AUC results were classified into excellent (AUC values of 
0.9-1.0), good (AUC values of 0.8-0.9), fair (AUC values of 
0.7-0.8), poor (AUC values of 0.6-0.7), and failed (AUC 
values of 0.5-0.6) [19]. 
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III. RESULTS AND DISCUSSION 
Sixty-six subjects participated in this research. Healthy 
subjects consisted of 33 women, while ovarian cancer 
patients consisted of 33 women. The mean age of healthy 
subjects was 26.7 years old, while ovarian cancer patient 
was 45.9 years old. There were only 23 data available for 
staging and 25 data for chemotherapy. There were seven 
patients (stage I), three individuals (stage II), nine patients 
(stage III), and four patients (stage IV). For chemotherapy, 
20 patients had chemotherapy; five patients did not have 
chemotherapy (Table I).  
A purely deterministic basis cannot fully describe the 
complex biological systems as they often show nonlinear 
behavior. The pattern of EDTA-blood photo spectrum in 
time series data can is assessed using deterministic and 
stochastic approach. In this study, the deterministic and 
stochastic component is estimated by a quadratic equation. 
The baseline of the absorbance in time series data is 
estimated by the deterministic approach, whereas the random 
value of the absorbance is estimated by stochastic approach 
[20] using autocorrelation functions [21]. Data (or curve) 
fitting was carried out to determine the parameter value 
closest to the real data [22]. 
TABLE I 
BASIC CHARACTERISTIC OF STUDY SUBJECT  
No. Study group Number of Patients 
1 EOC patients 33  
2 Median age (range) 49  
3 Tumour stagingd 
a. Tumour stage I 
b. Tumour stage II 
c. Tumour stage III 







< 1-time Chemotherapy 




5 Healthy subjects  33  
6 Median age (range) 24  
dDenominator for % is a number of subjects of non-missing data for 
each category. 
 
According to the results of the t-test, there were 
significant differences between EOC patients and healthy 
controls only in parameter-1 (IP1) of the parameters based 
on the ENBS approach. However, there were significant 
differences in all parameters based on the EBS (RP1-6) 
approach (Table II). 
 
TABLE II 
THE PARAMETERS OF PATTERN OF EDTA-BLOOD PHOTO SPECTRUM IN  STUDY PARTICIPANTS BASED ON THE ENERGETICS OF NONBIOLOGICAL SYSTEM (ENBS) 
AND ENERGETICS OF BIOLOGICAL SYSTEM (EBS) APPROACH 
No. ENBS Approach 
Study group n IP1 IP2 IP3 
1 EOC patients 33 7.7E-11±6.7E-11 -5.6E-05±4.9E-05 4.9E+00±4.8E+00 
2 Healthy subjects 33 -5.8E-13±1.4E-12 3.9E-07±1.5E-06 -7.1E-02±4.1E-01 
3 P  <0.01 >0.01 >0.01 
 n IP4 IP5 IP6 
4 EOC patients 33 1.2E-10±1.2E-10 -8.9E-05±8.9E-05 8.5E+00±8.2E+00 
5 Healthy subjects 33 9.9E-13±2.7E-12 
-9.3E-07±2.5E-06 -2.3E-02±5.2E-01 
6 p  >0.01 >0.01 >0.01 
EBS Approach 
 n RP1 RP2 RP3 
7 EOC patients 33 1.4E-02±1.2E-03 -1.3E-02±1.3E-03 1.0E-02±1.7E-03 
8 Healthy subjects 33 -3.7E-03±2.1E-03 2.5E-03±2.5E-03 -1.6E-03±2.1E-03 
9 p  <0.01 <0.01 <0.01 
 n RP4 RP5 RP6 
10 EOC patients 33 7.5E-03±4.1E-04 -7.7E-03±5.1E-04 8.7E-03±9.0E-04 
11 Healthy subjects 33 3.1E-03±9.1E-04 -3.7E-03±6.2E-04 -3.6E-04±6.5E-04 
12 p  <0.01 <0.01 <0.01 
IP: ideal parameter; RP: real parameter. 
 
The AUC of parameters based on EBS approach is larger 
than the AUC of parameters based on the ENBS approach. 
The AUC of ENBS parameter was 0.663, 0.704, 0.546, 
0.611, 0.619, and 0.676 and the AUC of EBS parameter was 
0.886, 0.855, 0.765, 0.909, 0.897, and 0.789 (Fig. 1, Table 
III).  
TABLE III 
THE PERFORMANCE OF THE PARAMETERS OF PATTERN OF EDTA-BLOOD 















     
LB UB 
ENBS Approach 
IP1 0.663 0.068 0.530 0.797 48.5 100.0 1.0E-12 
IP2 0.704 0.066 0.575 0.832 42.4 100.0 -1.3E-06
IP3 0.546 0.072 0.404 0.688 24.2 97.0 3.2E-01 
IP4 0.611 0.071 0.472 0.749 57.6 66.7 7.2E-11 
IP5 0.619 0.070 0.481 0.757 84.8 39.4 -2.7E-05
IP6 0.676 0.067 0.544 0.808 60.6 72.7 4.5E+00 
EBS Approach 
RP1 0.886 0.043 0.801 0.971 100.0 93.9 5.0E-04 
RP2 0.855 0.049 0.759 0.950 100.0 90.9 6.3E-04 
RP3 0.765 0.060 0.648 0.883 84.8 81.8 -1.1E-03
RP4 0.909 0.039 0.833 0.985 100.0 100.0 9.4E-03 
RP5 0.897 0.041 0.816 0.978 100.0 97.0 -8.8E-03
RP6 0.789 0.018 0.676 0.902 93.9 81.8 9.8E-03 
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1-specificity (false positive rate)
 
 
Marker AUC (95% CI)
IP1 0.66345 (0.52976, 0.79715)
RP1 0.88613 (0.80106, 0.97121)
Notes:  
AUC: area under the ROC curve; SE: standard error; CI: confidence 
intervals; UB: Upper bound; LB: lower bound; ENBS: energetics of non-
biological systems; EBS: energetics of biological systems; IP: ideal 
parameter; RP: real parameter. 
 
The AUC of parameter-4 is the largest in all of the 
parameters (0.909, CI: 0.833 - 0.985). The parameters based 
on EBS approach had higher diagnostic efficiency than 





























































































Fig. 1 ROC curves of parameters based on ENBS (ideal parameter, IP) and 
EBS approach (real parameter, RP) for EOC patients versus healthy 
controls, i.e.:(a)IP1,RP1; (b)IP2,RP2; (c)IP3,RP3; (d)IP4, RP4; (e)IP5, RP5; 
and(f)IP6, RP6.  
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The most sensitive biomarker to see the response of 
patients after chemotherapy of ovarian cancer is CA125. 
CA125 is not very effective because it exists in both cancer 
patients and advanced-diseased patients. “CA125 increases 
only 50% of stage I EOC and 75% to 90% of patients with 
advanced disease” [23].CA125cannot distinguish early-stage 
EOC and normal individuals [24]. This is because, at very 
low concentrations, the presence of CA125 cannot be 
detected [25] - [27]. In addition, the cost of CA125 
examinations is expensive [27], [28]. 
A new method is introduced to diagnose early-stage EOC 
by measuring the change of the erythrocyte sedimentation 
rate using the spectrophotometric method. As erythrocytes 
precipitates, plasma occupies the top region of the blood 
column. Macromolecules (rouleaux) were formed during the 
aggregation period when erythrocytes adhere together. Then 
the cells start to settle that can be monitored using the 
spectrophotometric method by calculating the water content 
of biological tissues in the upper region of the blood column 
in time series data [12]. 
In the early stages of cancer, the levels of proteins 
secreted as biomarkers are very low. The low level of 
biomarkers cannot be detected using the current method 
[25], [26]. The presence of biomarkers will change the zeta 
potential of erythrocyte (ZPE) in blood-EDTA [29], [30], so 
that it will affect the equilibrium of erythrocyte aggregation, 
such as the following: 
nE <===> En(2) 
With E is erythrocyte and n is the number of erythrocytes. 
Based on Eq. 2, this method is effective because a small 
change in the concentration affects the absorbance change 
gradient at a particular time in the erythrocyte absorbance 
pattern. The markers change the Zeta potential value so that 
the aggregation and disaggregation rates change. This is 
because a biomarker is a protein. Every protein consists of 
amino acid residue with different composition or sequence. 
A different amino acid residue sequence causes a different 
tertiary structure because of foldering. Each amino acid has a 
specific acid balance. Hence, it affects a specific value of the 
Zeta potential. Overall, this may change the erythrocyte 
absorbance pattern. Furthermore, this method is efficient 
because it only uses EDTA, and no reagent is needed, 
whereas other methods (CA125) need specific antibody and 
enzyme.   
In equation (2) if the equilibrium shifts to the right, it will 
produce a decreasing absorbance reading, whereas if the 
equilibrium shifts to the left, it will increase absorbance 
readings [31]. When equilibrium occurs, it will produce a 
constant absorbance reading. Thus, the existence of 
biomarkers will influence the pattern of absorbance patterns 
with time. 
Biomarkers affect the balance of erythrocyte aggregation, 
when the balance shifts to the right, erythrocyte aggregation 
occurs; conversely, if the balance shifts to the left, 
erythrocyte disaggregation occurs. In this study, the type of 
aggregation and the repetition of aggregation in EOC 
patients differed from those in healthy controls (Fig. 2-4 and 
Table III, IV). Repetition of aggregation in patients in the 
EOC group which were not found in the normal group was 
14 types of aggregate from total of 87 aggregates, i.e.: 
aggregate-1 to 14 each 10, 23, 16, 8, 14, 4, 3, 2, 1, 2, 1, 1, 1, 
and 1. In normal group which was not found in the EOC 
group was seven types aggregate from the total of 124 
disaggregate. There are both EOC and normal group = 55 
aggregates. Repetition of disaggregation in patients in the 
EOC group which were not found in the normal group was 
ten types from the total of 115 disaggregate, and in normal 
group which was not found in EOC group was nine types of 
disaggregate from a total of 104 disaggregate. There are both 






































Fig. 2 Biomarker fingerprints in time series data of absorbance of EDTA-










Fig. 3 Type and repetition of erythrocyte aggregation of EDTA-blood in 
EOC patients and healthy controls; 14 (87): 14 types of aggregate from a 
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Fig. 4 Type and repetition of erythrocyte disaggregation of EDTA-blood in 
EOC patients and healthy controls; 10 (115): 10 types of disaggregate from 
115 disaggregates; nine (104): nine types of disaggregate from 104 
disaggregates. 
TABLE IV 
ERYTHROCYTE AGGREGATION OF EDTA-BLOOD IN EOC PATIENTS AND 
NORMAL SUBJECTS 




































1 0.031 10 0.059 31 
2 0.063 23 0.118 28 
3 0.094 16 0.176 34 
4 0.125 8 0.235 20 
5 0.156 14 0.294 6 
6 0.188 4 0.412 4 
7 0.219 3 0.529 1 
8 0.25 2 
 
9 0.281 1 
10 0.313 2 
11 0.375 1 
12 0.406 1 
13 0.438 1 
14 0.625 1 
 
The detection method in this study has no side effects 
because the examination only uses blood samples. Thus, the 
method in this study can replace the CA125 examination 
method. Before the occurrence of cancer, a random mutation 
happens, which produces various kinds of biomarkers, i.e., 
not only CA125. All of these biomarkers affect the 
erythrocytes such that they affect the photo spectrum pattern 
of the EDTA-blood. 
Statistically, time-series signals in the form of photo-
spectrum are discerned into deterministic and stochastic 
components. In a prediction setting, the occurrence of the 
stochastic system degrades the deterministic portion of the 
signal. The portion of the predictable variance equals the 
variance of the deterministic component. In this report, the 
component of the signal that can be predicted from several 
previous time samples functions as the basis for the 
deterministic component, whereas the component for which 
such prediction is impossible determines the stochastic 
components. To analyze the pattern of EDTA-blood photo 
spectrum as time-series data, we used the deterministic and 
stochastic approach based on ENBS and EBS [32], [33].In 
this study, the deterministic and stochastic component is 
estimated by a quadratic equation, whereas autocorrelation 
functions estimate the stochastic component. These two 
estimates were carried out by fitting the data (or curve) to 




ERYTHROCYTE DISAGGREGATION OF EDTA-BLOOD IN EOC PATIENTS AND 
NORMAL SUBJECTS 
 
Overall, the value of sensitivity and specificity can be 
used to identify the quality of a method, in this case, a 
method for detecting biomarkers. In this study, the 
sensitivity and specificity of the ENBS approach were low 
(average = 53.0 and 79.3, respectively). While the sensitivity 
and specificity of the EBS approach are higher (average = 
96.5 and 90.9, respectively). (Figure 1, Table III). This 
shows that the use of the EBS approach to detect biomarkers 
that affect cellular interactions in EDTA-blood from 
research subjects is better than the ENBS approach. Thus, it 
can be concluded that to detect the presence of biomarkers in 
EOC patients, it is better to use the EBS approach compared 
to using the ENBS approach. From Figure 1 and Table III, it 
is also seen that the AUC value based on the ENBS 
approach is low (average = 0.637). This shows that with the 
ENBS approach; the presence of biomarkers in blood plasma 
that affect ZPE [34] is less detectable. While the AUC value 
based on EBS is higher (average= 0.850), which shows that 
with the EBS approach, the presence of biomarkers can be 
detected [19, from the following table, can be seen from the 
highest AUC value in parameter four based on EBS 
approach (= 0.909). The values of sensitivity and 
specifications are based on Table 3 in the columns of specify 
and sensitivity. This shows that the presence of biomarkers 





































1 0.031 24 0.059 31 
2 0.063 32 0.118 38 
3 0.094 19 0.176 12 
4 0.125 16 0.235 8 
5 0.156 5 0.294 6 
6 0.188 2 0.353 5 
7 0.219 9 0.412 2 
8 0.25 5 0.471 1 
9 0.313 2 0.529 1 




EOC patients Healthy controls 
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was detected very well by analyzing the pattern of EDTA-
blood photos spectrum in EOC patients based on ENBS 
approach on parameter 4 (RP4). All available markers (not 
only CA125) give specific absorbance patterns. Compared 
with CA125, the sensitivity and specificity of parameters 
based on EBS approach were higher than CA125 (100% and 
100% for RP4; 72.7% and 64.5% for CA125) [35]. 
Compared with previous research, this research is more 
convincing. First, data that is more comprehensive is 
presented in this study for diagnostic research, such as cut-
off values, sensitivity, and specificity. Second, this research 
is the first study on cancer detection without isolating 
biomarkers. Biomarkers in EDTA-blood affect cellular 
interactions, through ZPE changes when viscosity dispersion 
and dielectrics are permitted to be included and applied to 
Smoluchowski theory [36]. Thus, the smallest biomarker 
level will be detected using this method. Before the 
occurrence of cancer, the presence of one or more mutations 
that trigger tumor growth will affect the composition of 
proteins in blood plasma, which will affect ZPE. Therefore, 
with this method, the biomarkers of EOC patients will be 
detected. 
From this study, new parameters were found that could be 
used as diagnostic tools to identify the presence of EOC, the 
values of all parameters based on the EBS approach differed 
significantly between EOC patients and healthy controls (p = 
2.65E-25, 3.16E-21, 1.28E-03, 7.62E-37, 5.39E-28, 1.49E-
05  for real parameter-1to 6). The ROC curve analysis 
showed that the predictive ability of EBS parameters as a 
biomarker reflection of EOC was better than CA125. 
Senility and specificity for EBS parameters = 100.0%, 
100.0%, 84.8%, 100.0%, 100.0%, and 93.9%; and 93.9%, 
90.9%, 81.8%, 100.0%, 97.0%, and 81.8% respectively; 
while sensitivity and specificity for CA125 = 72.7% and 
64.5% respectively [35] (Table III). The effectiveness of this 
method is in expensive, and the only sample needed is blood. 
Furthermore, the high sensitivity and specificity of this 
method show its efficiency.  
IV. CONCLUSION 
We have succeeded in discovering a new method for 
detecting biomarkers secreted by cancer cells in EOC 
patients. This method is applied by analyzing the patterns of 
absorbance in EDTA-blood, which is based on the concept 
of EBS to determine the parameters that indicate the 
presence of biomarkers from EOC patients. This method can 
replace the CA125 examination because this method has 
greater sensitivity and specificity than CA125 examination. 
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